Mode
Text Size
Log in / Sign up

Type 2 Diabetes

Part of Diabetes

Subtypes of Type 2 Diabetes

Type 2 Diabetes Mellitus 84

379 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 2 Diabetes

346 trials tracked for Type 2 Diabetes: 156 in phase 3 or 4 and 64 with published results. The most-cited published study has 775 citations.

346Trials tracked
156Phase 3 & 4
0Recruiting
64With published results
Phase distribution
Phase 4 62 Phase 3 94 Phase 2 32 Phase 1 14 Other / NA 144
  1. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Completed · 775 cited
  2. Phase 3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed · 643 cited
  3. Phase 3 Add-on to Thiazolidinedione (TZD) Failures Completed · 408 cited
  4. Phase 3 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed · 363 cited
  5. Phase 3 A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin Completed · 346 cited
  6. Phase 3 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets Completed · 310 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM Completed · 274 cited
  2. Phase 4 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed · 265 cited
  3. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes Completed · 259 cited
  4. Phase 4 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Completed · 250 cited
  5. Phase 3 A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Completed · 226 cited
  6. Phase 4 An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Completed · 197 cited
  7. Phase 3 RISE Pediatric Medication Study Completed · 174 cited
  8. Phase 4 Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes Completed · 168 cited
  9. Phase 3 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin Completed · 156 cited
  10. Phase 3 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 150 cited
  11. Phase 3 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes Completed · 150 cited
  12. Phase 4 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed · 135 cited
  13. Phase 3 Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients Completed · 134 cited
  14. Phase 4 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis Completed · 129 cited
  15. Phase 3 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Completed · 129 cited
  16. Phase 4 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency Completed · 101 cited
  17. Phase 3 Actos Now for Prevention of Diabetes (ACT NOW) Completed · 101 cited
  18. Phase 4 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Completed · 100 cited
  19. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) Completed · 100 cited
  20. Phase 4 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed · 98 cited
  21. Phase 3 Vitamin D for Established Type 2 Diabetes (DDM2) Completed · 94 cited
  22. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Completed · 87 cited
  23. Phase 3 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 86 cited
  24. Phase 4 Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes Completed · 85 cited
  25. Phase 3 Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Completed · 72 cited
  26. Phase 4 Effects of Metformin on Hepatic FFA Metabolism Completed · 65 cited
  27. Phase 4 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) Completed · 62 cited
  28. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time Completed · 61 cited
  29. Phase 4 Liraglutide and Peripheral Artery Disease Completed · 60 cited
  30. Phase 4 The Health Influences of Puberty (HIP) Study Completed · 48 cited
  31. Phase 4 Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients Completed · 47 cited
  32. Phase 3 Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes Completed · 47 cited
  33. Phase 3 RISE Adult Medication Study Completed · 46 cited
  34. Phase 4 Glargine U300 Hospital Trial Completed · 44 cited
  35. Phase 4 Linagliptin's Effect on CD34+ Stem Cells Completed · 42 cited
  36. Phase 3 Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus Completed · 42 cited
  37. Phase 4 Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients Completed · 38 cited
  38. Phase 3 Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients Completed · 38 cited
  39. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Completed · 37 cited
  40. Phase 4 Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans Completed · 35 cited
  41. Phase 3 Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) Completed · 32 cited
  42. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Completed · 32 cited
  43. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections Completed · 30 cited
  44. Phase 4 Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes Completed · 26 cited

Showing the 50 most-cited and recently-updated of 346 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 2 Diabetes: what the trials found

Orforglipron demonstrated significant efficacy in reducing HbA1c levels from baseline, with a reported reduction of -1.59 to -1.26 across study arms (p<0.001) 2. This treatment also significantly improved the proportion of patients achieving target HbA1c values below 7.0% and 6.5% 2.

Lorcaserin hydrochloride was shown to significantly reduce HbA1c levels in patients with T2DM at baseline (p<0.0001) 22. There was no significant difference between groups regarding the development or worsening of FDA-defined valvulopathy 22.

Subgingival chlorhexidine irrigation showed a statistically significant association between improvements in oral health (specifically probing depth) and improvements in systemic health (HbA1c) 1. However, it did not show a significant impact on oral health measures alone or an association with flow-mediated dilation 1.

Recent results — preliminary, needs further review

  • T2.coach was associated with lower mean HbA1c values compared to control groups (p=0.0085) 5.
  • A CGM-based titration algorithm in DiAs significantly improved Time in Range (3.9-10.0 mmol/L) and reduced Time Above 10.0 mmol/L (p=0.001) 16.
  • The DASH4D diet was associated with significant improvements in Systolic Blood Pressure (p<0.001) 6.
  • Multi-Caregiving Intervention showed a mean reduction in HbA1c of 0.53 to 0.57 over 6 months 9.

For the clinician treating this condition

  • Orforglipron is an established option for reducing HbA1c and achieving glycemic targets 2.
  • Lorcaserin hydrochloride provides significant reduction in HbA1c in patients with T2DM 22.
  • Oral health improvements (via subgingival chlorhexidine) are significantly associated with improved systemic HbA1c levels 1.

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Type 2 Diabetes: current evidence & treatments

Multiple pharmacological interventions show efficacy in type 2 diabetes management. SGLT2 inhibitors reduce all-cause mortality in heart transplant recipients 1 and provide robust prognostic benefits in heart failure 4, but increase diabetic ketoacidosis risk, especially with elevated HbA1c 22. GLP-1 receptor agonists may reduce cognitive decline 8 and show no increased ocular disorder risk 17, while semaglutide reduces kidney decline or death in chronic kidney disease 6. Metformin is associated with higher lactate concentrations during exercise 5, and paternal use shows no increased risk of major congenital malformations 23. Thiazolidinediones show lower hepatocellular carcinoma risk compared to other classes 21, and GLP-1RAs show lower risk of serious liver events versus DPP-4 inhibitors 18.

Lifestyle and behavioral interventions are effective. Resistance training reduces HbA1c by 0.62% and systolic blood pressure by 3.91 mmHg 24. Multicomponent behavioral interventions achieve sustained HbA1c reduction of 1.84% at 12-36 months 25. Eating later in the biological day is associated with impaired glucose regulation 14. Real-time continuous glucose monitoring improves HbA1c versus self-monitoring 19. Metabolic subtypes identify Japanese adults with prediabetes at different T2D risk 13. Preoperative comorbidities like type 2 diabetes are linked to reduced weight loss after bariatric surgery 7.

Genetic and molecular studies reveal insights into diabetes pathophysiology. Transcriptomic analysis identifies 337 high-confidence T2D-associated genes in pancreatic islets 3. A multi-ancestry meta-analysis identifies 37 loci linked to gestational diabetes, 7 novel 15. AI-driven cardiovascular risk prediction shows promise but bias and lack of diversity limit clinical use 16. Case reports highlight rare adverse effects: voglibose may cause leukopenia 10, and single-incision sleeve plus bypass shows short-term safety in 3 patients 2.

Key drugs in the evidence

semaglutide 35 SGLT2 inhibitors 30 GLP-1 receptor agonists 24 metformin 21 dapagliflozin 18 tirzepatide 12 DPP-4 inhibitors 11 dulaglutide 10 exenatide 8 liraglutide 8

Latest findings

AI-generated synthesis of 21 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Diabetes

Related studies from across the Diabetes family.

Fatty pancreas disorder is associated with higher odds of fatty liver and diabetes mellitus
Diabetes & Endocrinology Meta-analysis
Fatty pancreas disorder is associated with higher odds of fatty liver and diabetes mellitus Fatty pancreas disorder linked to higher risk of diabetes
This meta-analysis of 6,834 patients found that fatty pancreas disorder (FPD) is associated with a 7.87 odds ratio for fatty liver and a 3.1…
People with a fatty pancreas are much more likely to develop fatty liver disease and diabetes than those without the condition.
Indole-AhR-Treg axis proposed as context-dependent target for restoring tolerance in type 1 diabetes
Diabetes & Endocrinology Sys. Review
Indole-AhR-Treg axis proposed as context-dependent target for restoring tolerance in type 1 diabetes Gut Metabolites May Help Explain Type 1 Diabetes Immune Attack
This narrative review synthesizes mechanistic and translational evidence on microbiome-derived tryptophan indole metabolites (IAA, ICA, IPA)…
Gut bacteria make molecules that may calm the immune attack in type 1 diabetes. A new review explains how this could work, but human proof i…
Older age correlates with higher hearing-related symptom scores in adults with diabetes
ENT (Otolaryngology) Sys. Review
Older age correlates with higher hearing-related symptom scores in adults with diabetes Older Age Tied to More Hearing Symptoms in Diabetes
This cross-sectional study of 128 adults with diabetes found that older age is associated with higher hearing-related symptom scores. Sex wa…
In adults with diabetes, older age and being female were linked to more self-reported hearing symptoms, but the study cannot show cause.
Anti-inflammatory strategies may stabilize mental functioning and promote autonomic and metabolic homeostasis
Diabetes & Endocrinology Sys. Review
Anti-inflammatory strategies may stabilize mental functioning and promote autonomic and metabolic homeostasis Inflammation and Nerve Imbalance Linked to Anxiety and Metabolic Ills
This narrative review explores the roles of metainflammation, autonomic instability, and anti-inflammatory strategies in anxiety and cardiom…
A new review links chronic inflammation and unstable nerve signals to anxiety, obesity, and diabetes, but it is early, broad thinking, not p…
Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes
Psychiatry Sys. Review
Digital phenotyping enables real-time mental health monitoring and risk prediction in people with diabetes Digital Tools May Help Track Mental Health in People with Diabetes
This scoping review of 10 studies examines the use of digital phenotyping, including CGM and smartphone sensing, for mental health monitorin…
New digital tools like smartphone sensors and glucose monitors may help track and predict mental health issues in people living with diabete…
Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups
Neurology Sys. Review
Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups Common autoimmune conditions often occur alongside multiple sclerosis
This scoping review synthesizes evidence on immune-mediated comorbidities in multiple sclerosis. Autoimmune thyroid disease, type 1 diabetes…
People with multiple sclerosis often have other autoimmune conditions like thyroid disease or psoriasis, but the link to disease progression…
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women
Diabetes & Endocrinology Meta-analysis
Telemedicine for gestational diabetes reduces fasting glucose and gestational weight gain in women Telemedicine Shows Potential for Managing Gestational Diabetes Care
This meta-analysis of 3055 women with gestational diabetes found that telemedicine interventions associated with lower fasting glucose (MD -…
Telemedicine may help manage blood sugar and weight gain in pregnant women with gestational diabetes, though the evidence is currently limit…
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes
Nutrition & Obesity Medicine Sys. Review
High prevalence of vitamin B12 deficiency in South Asian pregnant women suggests risk for adverse outcomes Vitamin B12 deficiency is common among pregnant women in South Asia
This narrative review examines the prevalence of vitamin B12 deficiency in pregnant women in South Asia and its association with maternal an…
Up to 70% of pregnant women in South Asia may have low vitamin B12, a finding that could impact both mother and baby health.
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis
Drug Pipeline Meta-analysis
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis Herbal additions may improve outcomes for patients with diabetic osteoporosis
A network meta-analysis suggests that integrating specific Chinese polyherbal preparations with standard care improves bone density and gluc…
Combining specific herbal preparations with standard medicine may improve bone density and blood sugar for people with diabetic osteoporosis…
Environmental and early-life exposures may influence microRNA expression and immune pathways in Type 1 Diabetes
Diabetes & Endocrinology Sys. Review
Environmental and early-life exposures may influence microRNA expression and immune pathways in Type 1 Diabetes Early life factors and environmental triggers may impact Type 1 Diabetes
This narrative review explores how environmental factors and early-life exposures influence microRNA expression and pancreatic beta-cell fun…
New research explores how early life factors like infections and diet might influence how the body develops Type 1 Diabetes.
Diabetic Retinopathy Tied to Higher Dementia Incidence in Pooled Analysis
Diabetes & Endocrinology Meta-analysis
Diabetic Retinopathy Tied to Higher Dementia Incidence in Pooled Analysis Diabetes eye damage may link to higher risk of dementia
Pooled data from nearly 3 million patients link diabetic retinopathy to higher incident dementia, though crude analyses show no significant …
A large study of over 2 million people suggests that eye damage from diabetes is linked to a higher risk of developing dementia.
Acute hyperglycemic phenotypes are associated with increased mortality and mechanical ventilation in COVID-19 patients
Diabetes & Endocrinology Meta-analysis
Acute hyperglycemic phenotypes are associated with increased mortality and mechanical ventilation in COVID-19 patients High Blood Sugar Levels Linked to Worse COVID-19 Outcomes
This meta-analysis examines the association between acute hyperglycemic phenotypes and clinical outcomes in patients with COVID-19. The stud…
New data shows a link between specific high blood sugar patterns and a higher risk of severe outcomes for patients with COVID-19.

Questions about Type 2 Diabetes

Do GLP-1 receptor agonists increase the risk of retinopathy in type 2 diabetes?

Some evidence links GLP-1 receptor agonists to a modest increase in early-stage diabetic retinopathy, but findings are mixed and may depend on the specific drug and how quickly blood sugar drops.

Full answer →
Do GLP-1RAs help improve walking distance for those with diabetes and Peripheral Artery Disease?

Yes, GLP-1 receptor agonists (liraglutide, semaglutide) improve walking distance in people with type 2 diabetes and peripheral artery disease, based on a 2025 meta-analysis of randomized trials.

Full answer →
What common genes link Polycystic Ovary Syndrome and type 2 diabetes according to recent studies?

Recent studies link PCOS and type 2 diabetes through shared genetic variants, notably the insulin gene VNTR and epigenetic changes in metabolism-related genes.

Full answer →
What are the standard treatment options available for someone with Type 2 Diabetes?

Standard treatment for type 2 diabetes includes lifestyle changes (diet, exercise), metformin, other medications like GLP-1 agonists (e.g., semaglutide, tirzepatide), and sometimes insulin, along with monitoring blood sugar and managing cardiovascular risk.

Full answer →
What are the best lifestyle changes to manage Type 2 Diabetes effectively?

A Mediterranean diet, regular physical activity, weight loss, and digital health tools can effectively manage type 2 diabetes, with medication support as needed.

Full answer →
See all 5 questions about Type 2 Diabetes →